<DOC>
	<DOCNO>NCT00358878</DOCNO>
	<brief_summary>Primary : To evaluate efficacy satavaptan top conventional treatment treatment clinically evident ascites participant cirrhosis liver . Secondary : To evaluate tolerability safety satavaptan 52-week treatment period participant cirrhosis liver ascites . The one-year double blind placebo control period extend 2 year long term safety study ( PASCCAL-2 ) .</brief_summary>
	<brief_title>Cirrhotic Ascites Treatment With Satavaptan Patients With Ascites Due Cirrhosis Liver ( CATS )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Satavaptan</mesh_term>
	<criteria>Participants cirrhosis liver Participants clinically evident ascites primarily manage diet and/or diuretic Stable treatment ascites least previous 2 week without paracentesis Participants undergo one therapeutic paracentesis previous 6 month . Participants exist functional transjugular intrahepatic portosystemic shunt ( TIPS ) shunt Known hepatocellular carcinoma Participants ascites cardiac origin due peritoneal infection ( e.g . tuberculosis ) peritoneal carcinoma Participants previously expose satavaptan past 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Ascites</keyword>
	<keyword>Liver Cirrhosis</keyword>
</DOC>